


Mechanisms of Tumour Progression Group

Publications: 11

Q1: 7



RESEARCH ACTIVITY

■ Doctoral theses

Master Theses

Torres B. Prognostic and predictive role of Gasdermin B in cancer[dissertation]. Madrid: UAM: 2021(16/09/2021).

Director: Moreno Bueno G.

Final Degree Theses

Pizarro P. LOXL2 interacts with HuR to promote SOX9 mRNA stability[dissertation]. Madrid: UAM: 2021(15/06/2021).

Director: Portillo Pérez F

Jiménez Carretero V. Dominios de loxl2 implicados en la interacción proteína-

proteína[dissertation]. Madrid: UAM: 2021(23/05/2021).


Director: Portillo Pérez F.

■ Publications

• Barbachano A, Fernández-Barral A, Bustamante-Madrid P, Prieto I, Rodríguez-Salas N, Larriba

MJ, Muñoz A. Organoids and colorectal cancer. Cancers (Basel). 2021; 13(11): 2657. Review. IF: 6.575; Q2

• García-Estévez L, Calvo I, Pérez S, Gallegos I, Díaz E, Sampayo-Cordero M, Oltra SS, Moreno-Bueno G. Predictive role of leptin receptor (OB-R) overexpression in patients with early breast cancer receiving neoadjuvant systemic treatment. Cancers (Basel). 2021; 13(13): 3269. Article. IF: 6.575; Q2



- García-Estévez L, Cortés J, Pérez S, Calvo I, Gallegos I, Gema B. Obesity and breast cancer: a paradoxical and controversial relationship influenced by menopausal status. *Front Oncol.* 2021; 11: 705911. Review. IF: 5.738; Q2
- García-Estévez L, González-Martínez S, Moreno-Bueno G. The leptin axis and its association with the adaptive immune system in breast cancer. *Front Immunol.* 2021; 12: 784823. Review. IF: 8.786; Q1
- López-Menéndez C, Vázquez-Naharro A, Santos V, Dubus P, Santamaría PG, Martínez-Ramírez A, Portillo F, Moreno-Bueno G, Faraldo MM, Cano A. E2A modulates stemness, metastasis, and therapeutic resistance of breast cancer. *Cancer Res.* 2021; 81(17): 4529-44. Article. IF: 13.312; D1
- Rodríguez-Cobos J, Vinal D, Poves C, Fernández-Acenero MJ, Peinado H, Pastor-Morate D, Prieto MI, Bardenas R, Rodríguez-Salas N, Domínguez G. Delta Np73, TAp73 and delta 133p53 extracellular vesicle cargo as early diagnosis markers in colorectal cancer. *Cancers (Basel).* 2021; 13(9): 2240. Article. IF: 6.575; Q2
- Rosas-Alonso R, Colmenarejo-Fernández J, Peria O, Rodríguez-Antolín C, Esteban I, Ghanem I, Sánchez-Cabrero D, Losantos-García I, Palacios-Zambrano S, Moreno-Bueno G, de Castro J, Martínez-Marín V, Ibáñez-de-Cáceres I. Clinical validation of a novel quantitative assay for the detection of MGMT methylation in glioblastoma patients. *Clin Epigenetics.* 2021; 13(1): 52. Article. IF: 7.259; Q1
- Royo F, Azkargorta M, Lavín JL, Clos-García M, Cortazar AR, González-López M, Barcena L, del Portillo HA, Yáñez-Mo M, Marcilla A, Borrás FE, Peinado H, Guerrero I, Vales-Gómez M, Cereijo U, Sardon T, Aransay AM, Elortza F, Falcon-Pérez JM. Extracellular vesicles from liver progenitor cells downregulate fibroblast metabolic activity and increase the expression of immune-response related molecules. *Front Cell Dev Biol.* 2021; 8: 613583. Article. IF: 6.081; Q1
- Sarrio D, Martínez-Val J, Molina-Crespo A, Sánchez L, Moreno-Bueno G. The multifaceted roles of gasdermins in cancer biology and oncologic therapies. *Bba-Rev Cancer.* 2021; 1876(2): 188635. Review. IF: 11.414; D1
- Suárez H, Andréu Z, Mazzeo C, Toribio V, Pérez-Rivera AE, López-Martín S, García-Silva S, Hurtado B, Morato E, Pelaez L, Arribas EA, Tolentino-Cortez T, Barreda-Gómez G, Marina AI, Peinado H, Yanez-Mo M. CD9 inhibition reveals a functional connection of extracellular vesicle secretion with mitophagy in melanoma cells. *J Extracell Vesicles*

. 2021; 10(7): e12082. Article. IF: 17.337; D1

- Zamudio-Martínez E, Herrera-Campos AB, Muñoz A, Rodríguez-Vargas JM, Oliver FJ. Tankyrases as modulators of pro-tumoral functions: molecular insights and therapeutic opportunities. *J Exp Clin Canc Res.* 2021; 40(1): 144. Review. IF: 1.658; D1

Research projects

Moreno Bueno G, Matías-Guiu X. Targeting the most aggressive type of endometrial carcinoma. (GC-TRA18014MATI). *AECC.* 2018-2024.

Management centre: FMDA-UAM

Moreno Bueno G. Molecular characterization of Gasdermin B cytotoxic activity and its potential application for the treatment of cancer (GB-citotox). (PID2019-104644RB-I00). *MICINN.* 2020-2023.

Management centre: UAM

Moreno Bueno G. Targeting Gasdermin-B overexpression as a new therapeutic approach in Her2+ cancers. (AECCINVEST-2019GMB). *AECC.* 2019-2022.

Management centre: UAM

Domínguez Muñoz G. Identificación de los mecanismos implicados en la diseminación peritoneal del cáncer colorrectal. Papel de Deltanp73: implicaciones diagnósticas, pronósticas y terapéuticas (PI18/00473). *ISCIII.* 2019-2021.

Management centre: FIBHULP

Muñoz Terol A, Larriba Muñoz MJ. Estudio de los efectos de la vitamina D en la fisiología y patología del colon humano usando organoides y cultivos primarios de fibroblastos derivados de pacientes (PID2019-104867RB-I00). *MICINN.* 2020-2023.

Management centre: CSIC

Rodríguez Salas N, Muñoz Terol A. Cáncer colorrectal en población joven.


Estudio farmacogenómico en organoides y efectos del microambiente tumoral (ICI20/00057). *ISCIII.* 2021-2024.

Management centre: FIBHULP

Portillo Pérez F. LOXL2 y LOXL3: Descubriendo nuevas vulnerabilidades terapéuticas en la progresión tumoral (PID2019-111052RB-I00). *MICINN.* 2020-2023.

Management centre: UAM





■ Cibers & Retics

Cano García A, Moreno Bueno G. Networked Biomedical Research Center for Cancer (CIBERonc). ISCIII. (31/12/2022).

Management centre: FIBHULP

Muñoz Terol A. Networked Biomedical Research Center for Cancer (CIBERonc). ISCIII. (31/12/2022).

Management centre: FIBHULP

Muñoz Terol A. Red Temática de Receptores Nucleares en Cáncer, Metabolismo e Inflamación. (NuRCaMeIn). Ministerio de Ciencia, Innovación y Universidades (31/12/2020).

Management centre: FIBHULP

■ Patents and trademarks

García García JF, Martín Moreno AM, Roncador G, Martínez Torrecuadra JL, Moreno Bueno G, inventors; Fundación MD Anderson International España, Fundación Centro Nacional de Investigaciones Oncológicas (CNIO), assignees; Method for the diagnosis and/or prognosis of lymphomas. P201231304; 2012 August 14.

Hergueta Redondo M, Sanz PG, Rojo A, García JF, Moreno-Bueno G, inventors; UAM, CSIC, Fundación MD Anderson International España, assignees; Gasdermin B2 as a new biomarker of malignance

and resistance of Trastuzumab inhibitor in Her2+ tumors. P201231560; 2012 October 10.

Matías-Guiu Guía FJ, Dolcet Roca FJ, Reventós Puigjaner J, Colás Ortega E, Prat Díaz de Losada J, Palacios Calvo J, Abal Posada M, López López R, Moreno Bueno G, Gil Moreno A, inventors; Institut de Recerca Biomèdica de Lleida Fundació Doctor Pifarré, Universitat de Lleida, Fundació Hospital Universitari Vall d'Hebron-Institut de Recerca, Fundació Institut de Recerca de L'Hospital de la Santa Creu i Sant Pau, Servicio Andaluz de Salud, Servicio Galego de Saúde, Fundación MD Anderson International España, assignees. Method to predict risk of recurrence in endometrial carcinoma. Annexin-A2 as predictor biomarker of recurrent disease in endometrial cancer. EP14155510.2, PCT/EP2015/053387; 2014 February 18.

Olmeda Casadomé D, Moreno Bueno G, Portillo Pérez F, Cano García A, inventors; UAM, CSIC, assignees. Method for the diagnosis and/or prognosis of breast cancer. P200702342, PCT/ES2008/000563; 2007 August 28.

Olmeda Casadomé D, Peinado Selgas H, Portillo Pérez F, Nieto Toledano MA, Cano García A, inventors; UAM, assignee. Materials and methods for the derepression of the Ecadherin promoter. US20060003956; 2004 March 03.